| 1 |
34290520 | Clinical Observation of Gene Polymorphism of Olanzapine or Aprepitant in Prevention of CINV. | 2021 |
1 |
| 2 |
32230800 | Influence of Genetic Variation in COMT on Cisplatin-Induced Nephrotoxicity in Cancer Patients. | 2020 Mar 27 |
3 |
| 3 |
30732962 | Predictors of cisplatin-induced ototoxicity and survival in chemoradiation treated head and neck cancer patients. | 2019 Feb |
1 |
| 4 |
30113582 | [The analysis of the association of the polymorphic variants of the TPMT, COMT, and ABCC3 genes with the development of hearing disorders induced by the cisplatin treatment]. | 2018 |
2 |
| 5 |
28445188 | TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity. | 2017 Jun |
1 |
| 6 |
28560854 | Pharmacogenetic analysis of irreversible severe cisplatin-induced nephropathy: a case report of a 27-year-old woman. | 2017 Sep |
2 |
| 7 |
26774148 | Genetic risk factors of cisplatin induced ototoxicity in adult patients. | 2016 |
1 |
| 8 |
27142473 | Pharmacogenomics in Pediatric Patients: Towards Personalized Medicine. | 2016 Aug |
1 |
| 9 |
24193170 | Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity. | 2014 Mar |
1 |
| 10 |
25551397 | Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts. | 2014 |
7 |
| 11 |
23588304 | Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. | 2013 Aug |
1 |
| 12 |
23820299 | The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. | 2013 Aug |
3 |
| 13 |
23872836 | Genetics of cisplatin ototoxicity: confirming the unexplained? | 2013 Aug |
1 |
| 14 |
19898482 | Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. | 2009 Dec |
2 |